Orchard Therapeutics News and Activities

Orchard Therapeutics is owned by Kirin.

Kirin is one of the...

• Forbes Global 2000 (#1280);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Kirin is a company listed under the stock ticker 2503 (JP).

Kirin has a direct presence in 3 countries.

Kirin has 6 subsidiaries including Coca-Cola Beverages Northeast, Kyowa Chemical Industry and Kyowa Hakko Kirin.

They are in:

• Beverages29%
• Pharmaceuticals29%
• Other43%

View the org chart displaying its 13 main executives

Most searched biographies at Orchard Therapeutics

• Bobby Gaspar, Chief Executive Officer and Director
• Nicoletta Loggia, Chief Technical Officer
• Robin Kenselaar, Chief Commercial Officer

Create your alert
to follow the executive moves at Orchard Therapeutics.

Kirin has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Orchard Therapeutics

• Crossing the Blood-Brain Barrier to Treat Disease - Orchard Therapeutics
• News & Press Releases | Orchard Therapeutics
• Landmark Studies Shine A Light on the Need to Modernize the US Newborn Screening System - Orchard Therapeutics
• Rightsizing the U.S. Newborn Screening System – Orchard Therapeutics
• Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) | Orchard Therapeutics
• Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I | Orchard Therapeutics
• Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences | Orchard Therapeutics
• Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I | Orchard Therapeutics
• Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) | Orchard Therapeutics
• Press Releases | Orchard Therapeutics
• View more press releases Close

Social media about Orchard Therapeutics

• Orchard Therapeutics on Wikipedia, Google News & Yahoo Finance
• Orchard Therapeutics on LinkedIn, X (Twitter) & YouTube